JP2013501224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501224A5 JP2013501224A5 JP2012523104A JP2012523104A JP2013501224A5 JP 2013501224 A5 JP2013501224 A5 JP 2013501224A5 JP 2012523104 A JP2012523104 A JP 2012523104A JP 2012523104 A JP2012523104 A JP 2012523104A JP 2013501224 A5 JP2013501224 A5 JP 2013501224A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- tumor
- patient
- folate receptor
- clinical benefit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 102000006815 folate receptor Human genes 0.000 claims 20
- 108020005243 folate receptor Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 2
- 208000023965 endometrium neoplasm Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000008174 sterile solution Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
- -1 EC145 compound Chemical class 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23059509P | 2009-07-31 | 2009-07-31 | |
| US61/230,595 | 2009-07-31 | ||
| US34644410P | 2010-05-19 | 2010-05-19 | |
| US61/346,444 | 2010-05-19 | ||
| US35102210P | 2010-06-03 | 2010-06-03 | |
| US61/351,022 | 2010-06-03 | ||
| PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501224A JP2013501224A (ja) | 2013-01-10 |
| JP2013501224A5 true JP2013501224A5 (enExample) | 2013-09-12 |
Family
ID=43529728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523104A Pending JP2013501224A (ja) | 2009-07-31 | 2010-07-30 | 葉酸を標的とした診断及び処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120128587A1 (enExample) |
| EP (1) | EP2460013A4 (enExample) |
| JP (1) | JP2013501224A (enExample) |
| KR (1) | KR20120050462A (enExample) |
| CN (2) | CN104857534A (enExample) |
| AU (1) | AU2010278734A1 (enExample) |
| BR (1) | BR112012002064A2 (enExample) |
| CA (1) | CA2769754A1 (enExample) |
| IL (1) | IL217744A0 (enExample) |
| IN (1) | IN2012DN01708A (enExample) |
| NZ (1) | NZ598145A (enExample) |
| RU (1) | RU2012105641A (enExample) |
| WO (1) | WO2011014821A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2696627C (en) | 2007-08-17 | 2016-09-27 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| AU2011325982C1 (en) | 2010-11-12 | 2015-08-20 | Endocyte, Inc. | Methods of treating cancer |
| BR112013026352A2 (pt) * | 2011-04-12 | 2016-07-26 | Endocyte Inc | composição farmacêutica sólida |
| KR102354613B1 (ko) | 2012-11-15 | 2022-01-21 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| WO2015055796A1 (en) | 2013-10-16 | 2015-04-23 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
| HUE066137T2 (hu) | 2013-10-18 | 2024-07-28 | Novartis Ag | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére |
| JP6464166B2 (ja) | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| WO2015077303A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Patient selection method for inflammation |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| CA2973380A1 (en) * | 2015-01-11 | 2016-07-14 | Endocyte, Inc. | Cancer imaging agent |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| WO2018182776A1 (en) * | 2016-03-29 | 2018-10-04 | Endocyte, Inc. | Folate conjugate for use in targeting tumor associated macrophages |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US20190216935A1 (en) * | 2016-05-25 | 2019-07-18 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| CN120097930A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR042942A1 (es) * | 2003-01-27 | 2005-07-06 | Endocyte Inc | Conjugados de administracion de drogas de union de receptores de vitaminas |
| CN101111267B (zh) * | 2004-12-21 | 2012-12-05 | 尼克塔治疗公司 | 稳定的聚合物巯基试剂 |
| RU2007128036A (ru) * | 2004-12-23 | 2009-01-27 | Пердью Рисерч Фаундейшн (Us) | Способ получения изображения позитронно-эмиссионной томографией |
| JP5289935B2 (ja) * | 2005-03-16 | 2013-09-11 | エンドサイト，インコーポレイテッド | プテロイン酸およびその結合体の合成と精製 |
| WO2006105141A1 (en) * | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| MX2009004555A (es) * | 2006-10-25 | 2009-05-11 | Schering Corp | Metodos de tratamiento de cancer de ovario. |
| EP3569251A1 (en) * | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
-
2010
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/ja active Pending
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/ru not_active Application Discontinuation
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/pt not_active IP Right Cessation
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/zh active Pending
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/ko not_active Ceased
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en not_active Ceased
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/zh active Pending
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501224A5 (enExample) | ||
| JP7169297B2 (ja) | 再発膠芽腫（ｒｇｂｍ）の治療方法 | |
| JP2014510728A5 (enExample) | ||
| WO2004043389B1 (en) | Methods of treating cancer and related methods | |
| JP2015523397A5 (enExample) | ||
| JP2018184465A5 (enExample) | ||
| RU2012105641A (ru) | Фолатнацеленные диагностические средства и лечение | |
| US20220202826A1 (en) | Methods for treating gi tract disorders | |
| JP2020505425A5 (enExample) | ||
| JP2012513429A (ja) | 浣腸製剤およびその使用 | |
| JP2018035162A5 (enExample) | ||
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| BR112020012766A2 (pt) | medicamento para tratar câncer | |
| ITRM940328A1 (it) | Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario. - | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2017517553A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| CN108201543A (zh) | 水溶性富勒烯结构在制备治疗脂肪肝的药物中的应用 | |
| Paderni et al. | Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| Su et al. | Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles | |
| JP2002534379A5 (enExample) | ||
| JP2018538370A (ja) | デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用 | |
| JP2025015727A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 |